Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00107731 |
The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar I Disorder. The study consists of enrollment and 2 phases, the Open-label treatment Phase and the Randomized treatment Phase.
PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Condition | Intervention | Phase |
---|---|---|
Bipolar I Disorder |
Drug: quetiapine fumarate Drug: lithium Drug: divalproex |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Valproate) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients (Abbreviated) |
Estimated Enrollment: | 710 |
Study Start Date: | April 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | AstraZeneca Seroquel Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | D1447C00126 |
Study First Received: | April 7, 2005 |
Last Updated: | December 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00107731 |
Health Authority: | United States: Food and Drug Administration |
Bipolar I Disorder Manic Depressive Disorder Manic Depression |
Quetiapine Depression Bipolar Disorder Lithium Carbonate |
Depressive Disorder Valproic Acid Lithium |
Tranquilizing Agents Pathologic Processes Disease Therapeutic Uses Physiological Effects of Drugs Psychotropic Drugs |
Central Nervous System Depressants Antimanic Agents Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions |